Keyphrases
Heart Failure Patients
100%
Chronic Heart Failure
100%
Anemia
100%
Erythropoiesis-stimulating Agents
100%
Risk Ratio
42%
Hemoglobin
42%
Iron Therapy
42%
All-cause Mortality
28%
Exercise Tolerance
28%
B-type Natriuretic Peptide
28%
Heart Failure Hospitalization
28%
Clinical Outcomes
14%
Randomized Controlled Trial
14%
Quality of Life
14%
Adverse Events
14%
MEDLINE
14%
Cochrane Library
14%
Meta-analysis
14%
Embase
14%
Adverse Effects
14%
Low Dose Rate
14%
Ejection Fraction
14%
Clinical Benefit
14%
Small Sample Size
14%
Increased Mortality
14%
Exercise Duration
14%
Left Ventricular Ejection Fraction
14%
Patients with Chronic Heart Failure
14%
New York Heart Association Class
14%
VO2peak
14%
Targeted Treatment
14%
Placebo-controlled
14%
Clinical Safety
14%
Extracted Data
14%
Kidney Cancer
14%
Issue 3
14%
Cochrane Central Register of Controlled Trials
14%
Comorbid Conditions
14%
Safety Concerns
14%
Weighted Mean Difference
14%
Hemoglobin Level
14%
New York Heart Association Functional Class
14%
Dichotomous Data
14%
Continuous Data
14%
6-minute Walk Distance (6MWD)
14%
Hospitalization Risk
14%
Mortality Effect
14%
Mild Anaemia
14%
Anemia of Chronic Kidney Disease
14%
Class Quality
14%
Anemia Tolerance
14%
Quality of Life Indicators
14%
Medicine and Dentistry
Congestive Heart Failure
100%
Anemia
100%
Hematinic
100%
Iron Supplement
33%
Quality of Life
22%
Randomized Controlled Trial
22%
All Cause Mortality
22%
New York Heart Association Class
22%
Brain Natriuretic Peptide
22%
Exercise Tolerance
22%
Placebo
11%
Meta-Analysis
11%
Ejection Fraction
11%
Adverse Event
11%
Heart Left Ventricle Ejection Fraction
11%
Chronic Kidney Disease
11%
Adverse Effect
11%
Kidney Cancer
11%
Pharmacology, Toxicology and Pharmaceutical Science
Congestive Heart Failure
100%
Anemia
100%
Antianemic Agent
100%
Iron
33%
Randomized Controlled Trial
22%
All Cause Mortality
22%
Brain Natriuretic Peptide
22%
Adverse Event
11%
Placebo
11%
Kidney Cancer
11%
Chronic Kidney Failure
11%